Free tool
Healthcare stocks
We cover 142 companies in the Healthcare sector. The median market value in the group is $369.14M. Across the group, the median move over the past trading day is +0.32%. 54% of the 137 with a 200-day average trade above it. Price change over the past year runs from −40.7% to +80.7% across the middle 80 percent of the group, with a median of −5.8%. Across the group, 2 companies currently carry a tier A volume signal.
Other lists in this group
Table
142 of 2,203 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| VIMIAN.ST | Vimian Group AB (publ) | 35.35 SEK | +1.58% | +15.22% | +12.01% |
| EMBLA.CO | Embla Medical hf. | 30.15 DKK | +5.05% | −5.78% | −6.94% |
| GXE.DE | Lakefront Biotherapeutics NV | 24.68 EUR | +0.82% | −12.36% | −44.50% |
| DRW8.DE | Drägerwerk AG & Co. KGaA | 82.40 EUR | +8.42% | +52.87% | +53.42% |
| ATT.ST | Attendo AB (publ) | 117.90 SEK | +7.57% | +49.22% | +80.74% |
| ALVO-SDB.ST | Alvotech | 46.45 SEK | +33.67% | +1.57% | −39.57% |
| CLARI.PA | Clariane SE | 4.01 EUR | −0.89% | +2.14% | −6.95% |
| BONEX.ST | Bonesupport Holding AB (publ) | 224.40 SEK | +1.54% | +26.07% | −28.26% |
| DIA.WA | Diagnostyka S.A. | 167.60 PLN | +0.72% | −3.07% | −17.76% |
| NOLA-B.ST | Nolato AB (publ) | 51.80 SEK | +6.91% | −10.27% | −7.00% |
| RDC.DE | Redcare Pharmacy NV | 62.05 EUR | −10.46% | −6.06% | −23.82% |
| AMBEA.ST | Ambea AB (publ) | 173.60 SEK | +21.74% | +27.37% | +38.66% |
| GDS.PA | Ramsay Générale de Santé SA | 10.95 EUR | −0.45% | +17.24% | +9.50% |
| F9L.F | Joincare Pharmaceutical Group Industry Co.,Ltd. | 6.50 EUR | −2.99% | −48.41% | −48.41% |
| VITR.ST | Vitrolife AB (publ) | 95.10 SEK | +9.31% | −27.76% | −30.23% |
| CHEMM.CO | ChemoMetec A/S | 496.80 DKK | +15.59% | −26.35% | −3.94% |
| UPR.L | Uniphar plc | 370.00 GBP | −1.33% | +23.75% | +6.94% |
| SPI.L | Spire Healthcare Group plc | 237.00 GBP | +1.28% | +40.25% | +7.25% |
| BIOG-B.ST | BioGaia AB (publ) | 117.10 SEK | +1.39% | +15.05% | +13.96% |
| CVSG.L | CVS Group plc | 1,296.00 GBP | +3.27% | +1.73% | +2.05% |
| IVA.PA | Inventiva S.A. | 4.09 EUR | +3.94% | +0.99% | −14.63% |
| RHK.DE | RHÖN-KLINIKUM Aktiengesellschaft | 14.70 EUR | +13.08% | +15.81% | +24.49% |
| TTALO.HE | Terveystalo Oyj | 7.78 EUR | +4.29% | −16.20% | −22.31% |
| SPH.WA | Sopharma AD | 7.76 PLN | +8.08% | −39.14% | −38.71% |
| PHIL.MI | Philogen S.p.A. | 23.85 EUR | +1.06% | +6.10% | +4.75% |
| GUBRA.CO | Gubra A/S | 402.40 DKK | +6.23% | −24.64% | +4.79% |
| GXI.DE | Gerresheimer AG | 25.58 EUR | −9.23% | −7.99% | −39.73% |
| MEDCL.PA | MedinCell S.A. | 24.58 EUR | −6.18% | −0.57% | +41.92% |
| VETO.PA | Vetoquinol SA | 70.60 EUR | −3.29% | −16.35% | −6.37% |
| EUZ.DE | Eckert & Ziegler SE | 13.18 EUR | −4.56% | −12.19% | −24.60% |
| NEU.WA | NEUCA S.A. | 758.00 PLN | +1.34% | −9.22% | +15.02% |
| XVIVO.ST | Xvivo Perfusion AB (publ) | 278.80 SEK | +9.08% | +53.95% | +59.31% |
| PHN.MI | Pharmanutra S.p.A. | 81.50 EUR | −1.81% | +53.54% | +70.46% |
| DBV.PA | DBV Technologies S.A. | 2.53 EUR | +5.42% | −22.51% | +60.13% |
| SYNSAM.ST | Synsam AB (publ) | 59.50 SEK | +5.50% | −7.98% | +5.66% |
| MCAP.ST | MedCap AB (publ) | 554.50 SEK | +3.64% | +4.03% | −10.28% |
| DYVOX.ST | Dynavox Group AB (publ) | 76.70 SEK | +4.14% | −21.71% | −39.29% |
| OXB.L | Oxford Biomedica plc | 515.00 GBP | −5.68% | −21.37% | −9.81% |
| SFL.MI | Safilo Group S.p.A. | 1.85 EUR | +14.02% | −5.33% | +20.65% |
| AMS.L | Advanced Medical Solutions Group plc | 281.50 GBP | +0.36% | +29.14% | +38.01% |
| GNFT.PA | Genfit S.A. | 14.30 EUR | +5.30% | +172.38% | +310.45% |
| APOTEA.ST | Apotea AB (publ) | 75.30 SEK | +1.41% | −16.05% | −26.38% |
| ARJO-B.ST | Arjo AB (publ) | 28.38 SEK | +4.11% | −6.88% | −15.25% |
| UU8.F | Neurogene Inc. | 33.20 EUR | +21.17% | +29.18% | +165.60% |
| SNT.WA | Synektik Spólka Akcyjna | 338.40 PLN | −5.58% | +21.82% | +53.07% |
| EVT.DE | Evotec SE | 3.25 EUR | −6.22% | −41.07% | −45.75% |
| LBIRD.PA | Lumibird SA | 25.80 EUR | −1.53% | +23.06% | +57.43% |
| 2HQ0.DE | Tilray Brands, Inc. | 4.07 EUR | +21.13% | −48.80% | −67.56% |
| VLA.PA | Valneva SE | 2.89 EUR | +31.25% | −23.68% | −24.48% |
| AYJ.DE | Valneva SE | 2.98 EUR | +35.29% | −23.93% | −21.89% |
| CRW.L | Craneware plc | 1,272.00 GBP | +2.75% | −33.40% | −40.83% |
| EQS.PA | Equasens Société anonyme | 34.05 EUR | −1.02% | −24.08% | −25.98% |
| RAY-B.ST | RaySearch Laboratories AB (publ) | 181.70 SEK | +3.06% | −15.47% | −29.98% |
| BOI.PA | Boiron SA | 25.80 EUR | −5.84% | −14.29% | +21.99% |
| MEDI.OL | Medistim ASA | 263.00 NOK | +16.37% | +4.43% | +4.43% |
| J8J.F | TransThera Sciences (Nanjing), Inc. | 1.04 EUR | +0.97% | −90.91% | −90.91% |
| REG1V.HE | Revenio Group Oyj | 14.78 EUR | +16.56% | −33.12% | −38.54% |
| ALVIO.PA | Valerio Therapeutics Société anonyme | 0.81 EUR | +8.00% | +386.49% | +1198.08% |
| AGY.L | Allergy Therapeutics plc | 5.60 GBP | −5.08% | −52.94% | −30.00% |
| CVX.PA | Carvolix SA | 7.18 EUR | +17.70% | +293.42% | +293.42% |
| HNSA.ST | Hansa Biopharma AB (publ) | 43.30 SEK | +19.22% | +32.42% | +35.65% |
| AVCT.L | Avacta Group Plc | 69.50 GBP | +0.72% | +20.87% | +26.36% |
| CEVI.ST | CellaVision AB (publ) | 164.00 SEK | +7.47% | +10.88% | −5.28% |
| FYB.DE | Formycon AG | 18.44 EUR | −2.64% | −29.35% | −25.04% |
| LNA.PA | LNA Santé SA | 33.90 EUR | −2.87% | +38.37% | +11.88% |
| M12.DE | M1 Kliniken AG | 18.36 EUR | −2.86% | +1.10% | +37.84% |
| PRTC.L | PureTech Health plc | 121.20 GBP | +0.17% | −2.73% | −4.27% |
| NIOX.L | NIOX Group Plc | 66.60 GBP | +8.82% | −2.03% | −9.49% |
| EGTX.ST | Egetis Therapeutics AB (publ) | 7.87 SEK | +25.72% | +52.22% | +51.35% |
| CRNA.OL | Circio Holding ASA | 11.92 NOK | +37.80% | +877.05% | +1733.85% |
| VOX.WA | Voxel S.A. | 134.20 PLN | +6.85% | +10.36% | −18.11% |
| N3B.F | Anbio Biotechnology | 6.40 EUR | −24.26% | −62.13% | −83.42% |
| ALCLS.PA | Cellectis S.A. | 2.94 EUR | +16.59% | −30.30% | +27.74% |
| OPT.L | Optima Health plc | 240.50 GBP | +1.48% | +20.85% | +9.32% |
| HUM.ST | Humana AB (publ) | 71.70 SEK | +14.72% | +46.12% | +81.84% |
| ILM1.DE | Medios AG | 10.92 EUR | −1.62% | −25.61% | −26.32% |
| SBS.DE | Stratec SE | 22.85 EUR | +11.46% | +3.39% | −16.91% |
| NP5.DE | Newron Pharmaceuticals S.p.A. | 13.50 EUR | +8.87% | −48.77% | +47.70% |
| VICO.ST | Vicore Pharma Holding AB (publ) | 10.74 SEK | −0.74% | −2.19% | −1.29% |
| ANCR.L | Animalcare Group PLC | 335.00 GBP | 0.00% | +40.76% | +28.86% |
| MED.DE | MEDICLIN Aktiengesellschaft | 5.45 EUR | +31.64% | +51.39% | +75.81% |
| IDHC.L | Integrated Diagnostics Holdings plc | $0.55 | −9.00% | −21.91% | +16.89% |
| PIHLIS.HE | Pihlajalinna Oyj | 10.92 EUR | +5.61% | −21.46% | −28.38% |
| SUS.ST | Surgical Science Sweden AB (publ) | 50.85 SEK | +49.82% | +63.82% | −48.69% |
| TSTL.L | Tristel plc | 425.00 GBP | +1.19% | −2.84% | +19.76% |
| TRMED.OL | Thor Medical ASA | 6.76 NOK | +51.91% | +34.93% | +135.13% |
| TNG.PA | Transgene SA | 0.81 EUR | +12.57% | −15.34% | −22.50% |
| XUP.DE | Genfit S.A. | 14.08 EUR | −1.81% | +164.41% | +166.82% |
| ALMDT.PA | Median Technologies SA | 4.57 EUR | +15.84% | +3.98% | +90.42% |
| IDD.DE | Innate Pharma S.A. | 1.78 EUR | +12.80% | +12.80% | −2.52% |
| IPH.PA | Innate Pharma S.A. | 1.88 EUR | +19.01% | +16.21% | +1.19% |
| CLN.WA | Celon Pharma S.A. | 22.20 PLN | +5.21% | +8.82% | −3.06% |
| ALERS.PA | Eurobio Scientific Société anonyme | 19.80 EUR | −6.60% | −18.01% | −21.89% |
| STIL.ST | Stille AB | 225.00 SEK | −5.06% | +16.58% | −4.26% |
| AOTI.L | AOTI, Inc. | 142.50 GBP | +35.71% | +418.18% | +159.09% |
| ICE.WA | Medinice S.A. | 72.30 PLN | −6.35% | +330.36% | +595.19% |
| NORDH.OL | Nordhealth AS | 24.40 NOK | 0.00% | −32.22% | −32.22% |
| LIK.DE | LIMES Schlosskliniken AG | 570.00 EUR | −0.87% | +58.33% | +70.66% |
| ORIOLA.HE | Oriola Oyj | 0.90 EUR | −0.33% | −20.66% | −21.98% |
| BLC.PA | Bastide Le Confort Médical SA | 22.30 EUR | −2.83% | −6.50% | −16.32% |
| CARA.ST | Carasent AB (publ) | 25.25 SEK | +1.00% | −5.78% | −10.62% |
| FLERIE.ST | Flerie AB (publ) | 19.25 SEK | −3.02% | −40.94% | −48.05% |
| SANION.ST | Saniona AB (publ) | 11.83 SEK | −15.32% | −43.93% | −12.37% |
| DXRX.L | Diaceutics PLC | 143.50 GBP | +8.71% | +11.67% | +4.36% |
| ALCGM.PA | Cegedim SA | 10.26 EUR | +1.38% | −25.92% | −4.56% |
| VME.DE | Viromed Medical AG | 6.50 EUR | −15.03% | +71.96% | +85.71% |
| ALSEN.PA | Sensorion SA | 0.28 EUR | −0.71% | −17.01% | −14.20% |
| BINV.ST | BioInvent International AB (publ) | 24.30 SEK | +5.42% | −17.21% | −23.46% |
| NYKD.OL | Nykode Therapeutics AS | 4.64 NOK | +45.68% | +96.94% | +204.86% |
| PHO.OL | Photocure ASA | 54.00 NOK | −0.18% | −24.90% | −13.46% |
| ENE.WA | Centrum Medyczne ENEL-MED S.A. | 20.00 PLN | −0.99% | +11.11% | +16.28% |
| S2B.WA | Syn2bio S.A. | 63.00 PLN | −9.12% | +76.47% | +76.47% |
| MRC.WA | Mercator Medical S.A. | 60.40 PLN | +18.43% | +52.53% | +35.88% |
| CRNO-B.ST | Cereno Scientific AB (publ) | 4.71 SEK | +0.13% | −32.04% | −53.59% |
| BICO.ST | BICO Group AB (publ) | 19.92 SEK | +36.25% | −1.19% | −17.00% |
| GENO.ST | Genovis AB (publ.) | 20.15 SEK | +2.81% | −7.36% | −16.91% |
| V5P.F | Vytrus Biotech, S.A. | 17.60 EUR | +1.73% | +67.62% | +225.93% |
| EKF.L | EKF Diagnostics Holdings plc | 24.70 GBP | −5.00% | −6.97% | −15.56% |
| PAX.ST | Paxman AB (publ) | 57.50 SEK | +26.37% | +2.68% | −21.45% |
| SCLP.L | Scancell Holdings plc | 9.70 GBP | −2.02% | −2.02% | −7.62% |
| SLV.WA | Selvita S.A. | 28.60 PLN | +7.52% | −35.29% | −9.21% |
| HPHA.DE | Heidelberg Pharma AG | 2.52 EUR | −2.70% | +0.80% | −31.15% |
| SEDANA.ST | Sedana Medical AB (publ) | 12.02 SEK | +23.92% | +12.13% | −22.05% |
| MVIR.ST | Medivir AB (publ) | 2.08 SEK | +14.29% | +351.19% | +4.73% |
| XI3.F | Bioceltix S.A. | 20.40 EUR | +7.59% | −16.22% | −28.67% |
| CTX.WA | Captor Therapeutics Spolka Akcyjna | 74.00 PLN | −0.80% | −1.33% | +80.49% |
| BVXP.L | Bioventix PLC | 1,750.00 GBP | +15.89% | −5.88% | −30.64% |
| CRAD-B.ST | C-Rad AB (publ) | 35.30 SEK | −4.08% | +11.00% | +6.49% |
| HAMLET-B.ST | Hamlet BioPharma AB (publ) | 6.10 SEK | −17.57% | +7.02% | −0.81% |
| BCX.WA | Bioceltix S.A. | 80.50 PLN | −17.01% | 0.00% | −20.77% |
| SCP.WA | Scope Fluidics S.A. | 140.20 PLN | +19.83% | +0.29% | −9.90% |
| S84.F | Scope Fluidics S.A. | 27.90 EUR | +19.74% | −25.50% | −10.43% |
| RVU.WA | Ryvu Therapeutics S.A. | 18.40 PLN | +22.67% | −32.23% | −36.99% |
| GBT.PA | Guerbet SA | 7.92 EUR | +3.80% | −46.41% | −61.92% |
| SYNACT.ST | SynAct Pharma AB | 19.66 SEK | +12.99% | −12.43% | +10.82% |
| FARON.HE | Faron Pharmaceuticals Oy | 0.48 EUR | −0.92% | −78.79% | −79.42% |
| AZT.OL | ArcticZymes Technologies ASA | 20.80 NOK | +5.05% | −1.89% | −27.02% |
| ALCJ.PA | Crossject Société Anonyme | 1.48 EUR | −0.67% | −31.00% | −2.63% |
| FARN.L | Faron Pharmaceuticals Oy | 41.00 GBP | −4.65% | −78.97% | −79.24% |
| ALECR.PA | Eurofins-Cerep SA | 17,700.00 EUR | +8.59% | −0.56% | −3.80% |
| DVYSR.ST | Devyser Diagnostics AB (publ) | 59.70 SEK | −12.97% | −47.45% | −60.78% |
| EAPI.PA | Euroapi S.A. | 0.95 EUR | −24.88% | −56.91% | −68.63% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.